STOCK TITAN

[SCHEDULE 13D/A] Trevi Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

NEA amendments report current holdings and a dilution-driven decrease in stake. The filing discloses that New Enterprise Associates and affiliated reporting persons collectively beneficially own 15,074,080 shares of Trevi Therapeutics common stock, representing 12.0% of the outstanding class on the basis stated in the filing. NEA 16 is shown as the record owner of 10,421,428 shares and as holding warrants exercisable for 3,703,704 shares; NEA 18 VGE holds 948,948 shares. The ownership figures reflect shared voting and dispositive power among the reporting entities and individuals.

The amendment explains the decrease in the percentage ownership as resulting from an increase in the number of shares outstanding, and reiterates that the Funds acquired the shares for investment purposes. The filing states there are no present plans by the reporting persons to pursue corporate actions such as board changes, asset sales, or extraordinary transactions, and notes that no transactions were effected by the reporting persons in the last 60 days. Exhibits include the joint filing agreement and a power of attorney.

Le modifiche di NEA segnalano le partecipazioni attuali e una riduzione della quota causata dalla diluizione. Il deposito dichiara che New Enterprise Associates e le persone correlate detengono collettivamente la titolarità effettiva di 15,074,080 azioni ordinarie di Trevi Therapeutics, pari al 12,0% delle azioni in circolazione secondo quanto indicato nel documento. NEA 16 risulta come intestatario di registro di 10,421,428 azioni e titolare di warrant esercitabili per 3,703,704 azioni; NEA 18 VGE detiene 948,948 azioni. Le cifre riflettono la condivisione del potere di voto e di disposizione tra le entità e le persone segnalanti.

L'emendamento spiega che la diminuzione della percentuale è il risultato di un aumento del numero di azioni in circolazione e ribadisce che i Fondi hanno acquisito le azioni a fini di investimento. Il deposito precisa che non esistono piani attuali da parte dei segnalanti per intraprendere azioni societarie come cambi di consiglio, cessioni di attività o operazioni straordinarie, e rileva che non sono state effettuate operazioni dai segnalanti negli ultimi 60 giorni. Gli allegati includono l'accordo di deposito congiunto e una procura.

Las enmiendas de NEA informan las participaciones actuales y una disminución del porcentaje motivada por la dilución. La presentación revela que New Enterprise Associates y las personas informantes afiliadas poseen colectivamente de forma beneficiaria 15.074.080 acciones ordinarias de Trevi Therapeutics, lo que representa el 12,0% de la clase en circulación según lo indicado en el documento. NEA 16 figura como titular registral de 10.421.428 acciones y posee warrants ejercitables por 3.703.704 acciones; NEA 18 VGE posee 948.948 acciones. Las cifras reflejan el reparto del poder de voto y de disposición entre las entidades y las personas informantes.

La enmienda explica que la reducción del porcentaje se debe a un aumento en el número de acciones en circulación, y reitera que los Fondos adquirieron las acciones con fines de inversión. La presentación indica que no existen planes actuales por parte de los informantes para llevar a cabo acciones corporativas como cambios en el consejo, ventas de activos u operaciones extraordinarias, y señala que no se realizaron transacciones por parte de los informantes en los últimos 60 días. Los anexos incluyen el acuerdo de presentación conjunta y un poder notarial.

NEA의 수정 보고서는 현재 보유 지분과 희석으로 인한 지분율 감소를 알립니다. 제출서류에 따르면 New Enterprise Associates 및 관련 보고인들은 합산하여 Trevi Therapeutics 보통주 15,074,080주를 실질적으로 보유하고 있으며, 이는 제출서류 기준으로 전체 발행주식의 12.0%에 해당합니다. NEA 16은 10,421,428주를 명목 보유자로 기재되어 있고, 3,703,704주를 취득할 수 있는 워런트를 보유하고 있습니다; NEA 18 VGE는 948,948주를 보유하고 있습니다. 소유 수치는 보고 기관 및 개인들 간에 의결권과 처분권이 공유되어 있음을 반영합니다.

해당 수정서는 지분율 감소의 원인이 발행주식 수의 증가에 있다고 설명하며, 해당 펀드들이 주식을 투자 목적으로 취득했음을 재차 밝힙니다. 제출서류는 보고인들이 이사회 변경, 자산 매각 또는 기타 특별 거래와 같은 회사 관련 조치를 추진할 현재 계획이 없다고 명시하고, 지난 60일 동안 보고인들에 의해 거래가 이루어지지 않았다고 적시합니다. 첨부 서류로는 공동 제출 계약서와 위임장이 포함되어 있습니다.

Les amendements de NEA indiquent les participations actuelles et une baisse du pourcentage due à la dilution. Le dépôt révèle que New Enterprise Associates et les personnes déclarantes affiliées détiennent collectivement à titre bénéficiaire 15,074,080 actions ordinaires de Trevi Therapeutics, représentant 12,0% de la catégorie en circulation selon les indications du document. NEA 16 est inscrit en tant que titulaire enregistré de 10,421,428 actions et détient des bons de souscription exerçables pour 3,703,704 actions; NEA 18 VGE détient 948,948 actions. Les chiffres reflètent le partage des pouvoirs de vote et de disposition entre les entités et les personnes déclarantes.

L'amendement explique que la diminution du pourcentage résulte d'une augmentation du nombre d'actions en circulation et réaffirme que les Fonds ont acquis les actions à des fins d'investissement. Le dépôt indique qu'il n'y a aucun projet actuel de la part des déclarants visant à engager des actions d'entreprise telles que des changements au conseil d'administration, des cessions d'actifs ou des opérations extraordinaires, et note que aucune transaction n'a été effectuée par les déclarants au cours des 60 derniers jours. Les annexes comprennent l'accord de dépôt conjoint et une procuration.

NEA-Nachträge melden die aktuellen Bestände und eine auf Verwässerung zurückzuführende Verringerung der Beteiligungsquote. Die Einreichung legt offen, dass New Enterprise Associates und die verbundenen meldepflichtigen Personen zusammen wirtschaftlich Berechtigter von 15,074,080 Aktien der Stammaktien von Trevi Therapeutics sind, was nach den Angaben in der Einreichung 12,0% der ausstehenden Aktienklasse entspricht. NEA 16 ist als eingetragener Inhaber von 10,421,428 Aktien aufgeführt und hält Warrants, die für 3,703,704 Aktien ausübbar sind; NEA 18 VGE hält 948,948 Aktien. Die Besitzangaben spiegeln die gemeinsame Ausübung von Stimm- und Verfügungsrechten unter den meldenden Einheiten und Personen wider.

Das Nachtragsformular erklärt, dass der Rückgang des prozentualen Anteils auf eine Erhöhung der ausstehenden Aktienanzahl zurückzuführen ist, und bekräftigt, dass die Fonds die Aktien zu Investitionszwecken erworben haben. Es wird angegeben, dass die meldenden Personen derzeit keine Pläne haben, unternehmensbezogene Maßnahmen wie Vorstandswechsel, Veräußerungen von Vermögenswerten oder außergewöhnliche Transaktionen zu verfolgen, und vermerkt, dass in den letzten 60 Tagen keine Transaktionen durch die meldenden Personen vorgenommen wurden. Anlagen umfassen die gemeinsame Einreichungsvereinbarung und eine Vollmacht.

Positive
  • Collective beneficial ownership of 15,074,080 shares (12.0%) provides a clear, material stake in Trevi Therapeutics.
  • NEA 16 holds 10,421,428 record shares plus warrants for 3,703,704 shares, showing current holdings and potential future economic interest.
  • Filing explicitly states shares were acquired for investment purposes and disclaims present plans for corporate control actions, reducing immediate governance uncertainty.
Negative
  • Reported beneficial ownership decreased by more than 1% due to an increase in the number of shares outstanding, indicating dilution of stake.
  • All reporting persons report shared voting and dispositive power (no sole power), which may limit any individual reporting person’s unilateral control influence.

Insights

NEA retains a meaningful 12% stake but was diluted; no activist intentions disclosed.

The filing confirms NEA and affiliated entities collectively beneficially own 15,074,080 shares (12.0%), including warrants that add potential dilution. That stake size is large enough to influence investor perception of shareholder composition yet the amendment explicitly attributes a greater-than-1% decline in ownership percentage to an increase in shares outstanding rather than sale of holdings. The Funds state acquisition was for investment purposes and disclaim any current plans to change board composition or pursue corporate transactions, which reduces near-term governance risk. Investors should note the combination of record ownership and outstanding warrants when assessing potential future dilution and voting dynamics.

Shared voting/dispositive power across NEA entities creates coordinated influence without declared control actions.

The amendment details that voting and dispositive power over the Firm Shares is shared among multiple NEA entities and managers, and that individual reporting persons report no sole voting or dispositive power. The filing expressly denies present plans for board changes, asset sales, or other extraordinary transactions, and includes agreements governing joint filing and a power of attorney. From a governance standpoint, the disclosure clarifies ownership structure and intent: substantial collective ownership exists but no immediate control agenda is disclosed, making the filing informative but not an indicator of imminent governance activism.

Le modifiche di NEA segnalano le partecipazioni attuali e una riduzione della quota causata dalla diluizione. Il deposito dichiara che New Enterprise Associates e le persone correlate detengono collettivamente la titolarità effettiva di 15,074,080 azioni ordinarie di Trevi Therapeutics, pari al 12,0% delle azioni in circolazione secondo quanto indicato nel documento. NEA 16 risulta come intestatario di registro di 10,421,428 azioni e titolare di warrant esercitabili per 3,703,704 azioni; NEA 18 VGE detiene 948,948 azioni. Le cifre riflettono la condivisione del potere di voto e di disposizione tra le entità e le persone segnalanti.

L'emendamento spiega che la diminuzione della percentuale è il risultato di un aumento del numero di azioni in circolazione e ribadisce che i Fondi hanno acquisito le azioni a fini di investimento. Il deposito precisa che non esistono piani attuali da parte dei segnalanti per intraprendere azioni societarie come cambi di consiglio, cessioni di attività o operazioni straordinarie, e rileva che non sono state effettuate operazioni dai segnalanti negli ultimi 60 giorni. Gli allegati includono l'accordo di deposito congiunto e una procura.

Las enmiendas de NEA informan las participaciones actuales y una disminución del porcentaje motivada por la dilución. La presentación revela que New Enterprise Associates y las personas informantes afiliadas poseen colectivamente de forma beneficiaria 15.074.080 acciones ordinarias de Trevi Therapeutics, lo que representa el 12,0% de la clase en circulación según lo indicado en el documento. NEA 16 figura como titular registral de 10.421.428 acciones y posee warrants ejercitables por 3.703.704 acciones; NEA 18 VGE posee 948.948 acciones. Las cifras reflejan el reparto del poder de voto y de disposición entre las entidades y las personas informantes.

La enmienda explica que la reducción del porcentaje se debe a un aumento en el número de acciones en circulación, y reitera que los Fondos adquirieron las acciones con fines de inversión. La presentación indica que no existen planes actuales por parte de los informantes para llevar a cabo acciones corporativas como cambios en el consejo, ventas de activos u operaciones extraordinarias, y señala que no se realizaron transacciones por parte de los informantes en los últimos 60 días. Los anexos incluyen el acuerdo de presentación conjunta y un poder notarial.

NEA의 수정 보고서는 현재 보유 지분과 희석으로 인한 지분율 감소를 알립니다. 제출서류에 따르면 New Enterprise Associates 및 관련 보고인들은 합산하여 Trevi Therapeutics 보통주 15,074,080주를 실질적으로 보유하고 있으며, 이는 제출서류 기준으로 전체 발행주식의 12.0%에 해당합니다. NEA 16은 10,421,428주를 명목 보유자로 기재되어 있고, 3,703,704주를 취득할 수 있는 워런트를 보유하고 있습니다; NEA 18 VGE는 948,948주를 보유하고 있습니다. 소유 수치는 보고 기관 및 개인들 간에 의결권과 처분권이 공유되어 있음을 반영합니다.

해당 수정서는 지분율 감소의 원인이 발행주식 수의 증가에 있다고 설명하며, 해당 펀드들이 주식을 투자 목적으로 취득했음을 재차 밝힙니다. 제출서류는 보고인들이 이사회 변경, 자산 매각 또는 기타 특별 거래와 같은 회사 관련 조치를 추진할 현재 계획이 없다고 명시하고, 지난 60일 동안 보고인들에 의해 거래가 이루어지지 않았다고 적시합니다. 첨부 서류로는 공동 제출 계약서와 위임장이 포함되어 있습니다.

Les amendements de NEA indiquent les participations actuelles et une baisse du pourcentage due à la dilution. Le dépôt révèle que New Enterprise Associates et les personnes déclarantes affiliées détiennent collectivement à titre bénéficiaire 15,074,080 actions ordinaires de Trevi Therapeutics, représentant 12,0% de la catégorie en circulation selon les indications du document. NEA 16 est inscrit en tant que titulaire enregistré de 10,421,428 actions et détient des bons de souscription exerçables pour 3,703,704 actions; NEA 18 VGE détient 948,948 actions. Les chiffres reflètent le partage des pouvoirs de vote et de disposition entre les entités et les personnes déclarantes.

L'amendement explique que la diminution du pourcentage résulte d'une augmentation du nombre d'actions en circulation et réaffirme que les Fonds ont acquis les actions à des fins d'investissement. Le dépôt indique qu'il n'y a aucun projet actuel de la part des déclarants visant à engager des actions d'entreprise telles que des changements au conseil d'administration, des cessions d'actifs ou des opérations extraordinaires, et note que aucune transaction n'a été effectuée par les déclarants au cours des 60 derniers jours. Les annexes comprennent l'accord de dépôt conjoint et une procuration.

NEA-Nachträge melden die aktuellen Bestände und eine auf Verwässerung zurückzuführende Verringerung der Beteiligungsquote. Die Einreichung legt offen, dass New Enterprise Associates und die verbundenen meldepflichtigen Personen zusammen wirtschaftlich Berechtigter von 15,074,080 Aktien der Stammaktien von Trevi Therapeutics sind, was nach den Angaben in der Einreichung 12,0% der ausstehenden Aktienklasse entspricht. NEA 16 ist als eingetragener Inhaber von 10,421,428 Aktien aufgeführt und hält Warrants, die für 3,703,704 Aktien ausübbar sind; NEA 18 VGE hält 948,948 Aktien. Die Besitzangaben spiegeln die gemeinsame Ausübung von Stimm- und Verfügungsrechten unter den meldenden Einheiten und Personen wider.

Das Nachtragsformular erklärt, dass der Rückgang des prozentualen Anteils auf eine Erhöhung der ausstehenden Aktienanzahl zurückzuführen ist, und bekräftigt, dass die Fonds die Aktien zu Investitionszwecken erworben haben. Es wird angegeben, dass die meldenden Personen derzeit keine Pläne haben, unternehmensbezogene Maßnahmen wie Vorstandswechsel, Veräußerungen von Vermögenswerten oder außergewöhnliche Transaktionen zu verfolgen, und vermerkt, dass in den letzten 60 Tagen keine Transaktionen durch die meldenden Personen vorgenommen wurden. Anlagen umfassen die gemeinsame Einreichungsvereinbarung und eine Vollmacht.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


New Enterprise Associates 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA Partners 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA 16 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA 18 Venture Growth Equity, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA Partners 18 VGE, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
NEA 18 VGE GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/11/2025
Forest Baskett
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
Date:08/11/2025
Ali Behbahani
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
Date:08/11/2025
Carmen Chang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
Date:08/11/2025
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr.
Date:08/11/2025
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:08/11/2025
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:08/11/2025
Paul Walker
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
Date:08/11/2025
Comments accompanying signature:
This Amendment No. 7 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

How many Trevi Therapeutics (TRVI) shares do NEA and affiliates beneficially own?

The filing reports that the Reporting Persons collectively beneficially own 15,074,080 shares, representing 12.0% of the class on the basis stated in the filing.

What is NEA 16's position in TRVI according to the amendment?

NEA 16 is the record owner of 10,421,428 shares and holds warrants exercisable for 3,703,704 shares, which the filing treats as part of its potential beneficial ownership.

Did the reporting persons disclose any plans to change Trevi's management or take corporate actions?

No. The filing states the Funds have no present plans to effect board changes, asset sales, extraordinary transactions, changes to capitalization, or similar actions.

Why did NEA's percentage ownership decrease in this amendment?

The amendment reports the percentage decrease resulted from an increase in the number of Trevi common shares outstanding, not from sales by the reporting persons.

Have the reporting persons made any transactions in the last 60 days?

The filing states that none of the Reporting Persons effected any transaction in the last 60 days.
Trevi Therapeutics

NASDAQ:TRVI

TRVI Rankings

TRVI Latest News

TRVI Latest SEC Filings

TRVI Stock Data

925.50M
109.43M
0.75%
79.28%
8.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN